* Biodesix Inc reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -14 cents. The mean expectation of six analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -8 cents to -7 cents per share.

* Revenue rose 34.5% to $18.15 million from a year ago; analysts expected $18.61 million.

* Biodesix Inc's reported EPS for the quarter was a loss of 7 cents​.

* The company reported a quarterly loss of $10.26 million.

* Biodesix Inc shares had fallen by 4.5% this quarter and lost 7.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 6% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the healthcare facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Biodesix Inc is $3.00 This summary was machine generated from LSEG data November 1 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.07 -0.07 Met

Jun. 30 2024 -0.09 -0.08 Beat

Mar. 31 2024 -0.14 -0.14 Met

Dec. 31 2023 -0.11 -0.10 Beat